Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GI DYNAMICS, INC.GID · Entity 141502 | Director | December 16, 2019 | December 18, 2019 |
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GI DYNAMICS, INC.
Report date December 16, 2019 · Filed December 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2029-12-16 | Direct | 30,000 |
Reported balance
After 2019-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-16 · Grant · Acquired 30,000 · Balance 30,000 F1: The stock option grant was approved by the Issuer's board of directors on October 29, 2019, subject to stockholder approval, and by the stockholders of the Issuer on December 16, 2019. The stock options will fully vest on October 29, 2020. In the event of a change of control of the Issuer prior to October 29, 2020, the stock options will become vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option grant was approved by the Issuer's board of directors on October 29, 2019, subject to stockholder approval, and by the stockholders of the Issuer on December 16, 2019. The stock options will fully vest on October 29, 2020. In the event of a change of control of the Issuer prior to October 29, 2020, the stock options will become vested in full.
Indivior Pharmaceuticals, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,973 |
Ending reported balance
After 2026-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-12 · Tax withholding · Disposed 1,117 · Balance 6,455 F1: Shares used to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units on May 12, 2026. Row 2 · 2026-05-13 · Grant · Acquired 6,518 · Balance 12,973 F2: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,775 |
Reported balance
Holding disclosure · report date 2026-05-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,775 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares used to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units on May 12, 2026.
F2: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 20:12 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 6,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001715258-26-000007 · wk-form4_1778789524.xml · nonDerivative · entry 2 Thompson Juliet · CIK 0001715258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,973 F2 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:12 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | Tax withholdingCommon Stock | 1,117 | $38.28 | $42,758.76 |
DisclosureSEC source: 0001715258-26-000007 · wk-form4_1778789524.xml · nonDerivative · entry 1 Thompson Juliet · CIK 0001715258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,455 F1 · shares: Shares used to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units on May 12, 2026. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:07 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 3,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001715258-26-000004 · wk-form4_1769634439.xml · nonDerivative · entry 1 Thompson Juliet · CIK 0001715258 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,572 F1 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 10:05 UTC | GI DYNAMICS, INC. GID · Entity 141502 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001213900-19-026408 · ownership.xml · derivative · entry 1 Thompson Juliet · CIK 0001715258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-12-16 F1 · derivative.exercise_date: The stock option grant was approved by the Issuer's board of directors on October 29, 2019, subject to stockholder approval, and by the stockholders of the Issuer on December 16, 2019. The stock options will fully vest on October 29, 2020. In the event of a change of control of the Issuer prior to October 29, 2020, the stock options will become vested in full. Read SEC document |
| May 24, 2018 Filed May 29, 2018 16:05 UTC | GI DYNAMICS, INC. GID · Entity 141502 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0000899243-18-014246 · doc4.xml · derivative · entry 1 Thompson Juliet · CIK 0001715258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-08-22 F1 · derivative.exercise_date: The option grant was approved by the Issuer's board of directors on August 22, 2017, subject to shareholder approval, and by the shareholders of the Issuer on May 24, 2018. 1/3 of the option vests on August 22, 2018 and the remainder vests in eight substantially equal installments on a quarterly basis thereafter. In the event of a change of control of the Issuer, the option shall become vested in full. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.